Cart
sales@molnova.com
Autotaxin-IN-3
CAS No. 2156655-68-2
Autotaxin-IN-3( —— )
Catalog No. M26066 CAS No. 2156655-68-2
Autotaxin-IN-3 is an Autotaxin(ATX) inhibitor (IC50: 2.4 nM) sourced from patent WO2018212534A1 (compound 33).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 67 | In Stock |
|
| 2MG | 36 | In Stock |
|
| 5MG | 61 | In Stock |
|
| 10MG | 98 | In Stock |
|
| 25MG | 183 | In Stock |
|
| 50MG | 277 | In Stock |
|
| 100MG | 445 | In Stock |
|
| 200MG | 612 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAutotaxin-IN-3
-
NoteResearch use only, not for human use.
-
Brief DescriptionAutotaxin-IN-3 is an Autotaxin(ATX) inhibitor (IC50: 2.4 nM) sourced from patent WO2018212534A1 (compound 33).
-
DescriptionAutotaxin-IN-3 is an Autotaxin(ATX) inhibitor (IC50: 2.4 nM) sourced from patent WO2018212534A1 (compound 33).
-
In VitroAutotaxin is an enzyme which is responsible for the increase in lysophosphatidic acid in ascites and plasma, and it is a secretory enzyme important for converting lysophosphatidylchloine (LPC) into lysophosphatidic acid (LPA) as a bioactive signaling molecule.
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDE
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2156655-68-2
-
Formula Weight443.471
-
Molecular FormulaC22H21N9O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (563.75 mM)
-
SMILESO=C(Cc1nnc(o1)-c1cnc(NC2Cc3ccccc3C2)nc1)N1CCc2nn[nH]c2C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Resibufogenin
Resibufogenin is a cytotoxic steroid isolated from the Chinese drug ChanSu. Resibufogenin can inhibit rectifier potassium current ( I K ) and transient potassium current ( I A ), it has pathological effects on central nervous system.
-
Ensifentrine
Ensifentrine is a PDE3/4 inhibitor, although its affinity for PDE3(IC50: 0.4 nM) is 3,440 times higher than that for PDE4(IC50: 1479 nM), that is under clinical development for the treatment of asthma and COPD and, potentially, cystic fibrosis.
-
PF 05180999
PF-05180999 (PF 5180999) is a potent, selective, brain-penetrating and orally bioavailable phosphodiesterase 2A (PDE2A) inhibitor with IC50 of 1 nM.
